ESOU 2019

REVIEW UroToday

Viewing 1-20 of 55 articles

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Surgery

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Hypofractionation Radiation Therapy

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Focal Therapy

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Active Surveillance

ESOU 2019: An Update in Prostate Cancer Prevention

ESOU 2019: Treating Primary Metastatic Disease, a Case for Surgery Plus or Minus Radiotherapy

ESOU 2019: Symptomatic Metastatic Castration-sensitive Hormone-naïve Prostate Cancer: Evidence from CHAARTED, LATITUDE, and STAMPEDE

ESOU 2019: Oligo-Metastatic Disease Today - Diagnostic and Treatment

ESOU 2019: Debate: T2 Renal Tumors Best Surgical Treatment: Radical Nephrectomy

ESOU 2019: Debate: T2 Renal Tumors Best Surgical Treatment: Partial Nephrectomy

ESOU 2019: Risk Stratification for Active Surveillance

ESOU 2019: Surgery: High Quality Local Treatment in High Risk Localized Prostate Cancer

ESOU 2019: Radiotherapy: High Quality Local Treatment in High Risk Localized Prostate Cancer

ESOU 2019: Best of Uro-Oncology 2018 – Urothelial Cancer

ESOU 2019: Revolution in the First Line Treatment for Metastatic Renal Cell Carcinoma: Where Do We Stand?

ESOU 2019: Best of Uro-Oncology 2018 - Prostate Cancer

ESOU 2019: Adjuvant Therapy after Nephrectomy for High Risk Renal Cell Carcinoma: The Oncologist's Perspective

ESOU 2019: Cytoreductive Nephrectomy: What are the Current Recommendations?

ESOU 2019: Adjuvant Therapy after Nephrectomy for High Risk Renal Cell Carcinoma: The Urologist's Perspective

ESOU 2019: Best of Uro-Oncology 2018: Renal Cancer

1
2
3